<SEC-DOCUMENT>0001571049-16-011076.txt : 20160125
<SEC-HEADER>0001571049-16-011076.hdr.sgml : 20160125
<ACCEPTANCE-DATETIME>20160125164003
ACCESSION NUMBER:		0001571049-16-011076
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160125
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160125
DATE AS OF CHANGE:		20160125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		161359162

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1600238_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>January 25, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Phibro
Animal Health Corporation</B></FONT></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>01-36410</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>13-1840497</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Glenpointe Centre East, 3rd Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>300 Frank W. Burr Boulevard, Suite 21</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Teaneck, New Jersey</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 45%"><FONT STYLE="font-size: 10pt"><B>07666-6712</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; text-align: center; font-style: normal"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code:<B> (201) 329-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.01. Completion of Acquisition or Disposition of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 25, 2016, Phibro Animal Health
Corporation ( &ldquo;<B><I>Phibro</I></B>&rdquo;) completed its previously announced acquisition (the &ldquo;<B><I>Acquisition</I></B>&rdquo;)
of the Sellers&rsquo; Business (as defined herein) and the Assets (as defined herein), pursuant to the Asset Purchase Agreement,
dated as of January 12, 2016 (the &ldquo;<B><I>Agreement</I></B>&rdquo;), by and among Phibro, MVP Laboratories, Inc., a Nebraska
corporation (&ldquo;<B><I>MVP</I></B>&rdquo;), Mary Lou Chapek (the &ldquo;<B><I>Principal Shareholder</I></B>&rdquo;) and AVP,
LLC, a Nebraska limited liability company (&ldquo;<B><I>LLC</I></B>&rdquo; and, collectively with MVP and the Principal Shareholder,
the &ldquo;<B><I>Sellers</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Sellers, through MVP, are engaged in
the registration, development, manufacturing, marketing, sale and distribution to veterinary clinics and livestock operations of
vaccines, adjuvants and other products (&ldquo;<B><I>Sellers&rsquo; Business</I></B>&rdquo;). MVP is the manufacturer of an autogenous
vaccine against porcine reproductive and respiratory syndrome that Phibro exclusively distributes pursuant to an agreement between
Phibro and MJ Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Agreement, the Sellers&rsquo;
Business and all of the assets used or held for use in the conduct of the Sellers&rsquo; Business, including intellectual property,
working capital, manufacturing equipment and real property and facilities owned by MVP and LLC (the &ldquo;<B><I>Assets</I></B>&rdquo;),
were acquired by Phibro for an aggregate purchase price of approximately $46.5 million (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;).
The Purchase Price is subject to net working capital and certain other adjustments after closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01. Regulation FD Disclosure.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 25, 2016, Phibro issued a press
release announcing completion of the Acquisition. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in the press release
is being furnished and shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of, or otherwise regarded as filed
under, the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), nor shall it be deemed incorporated by
reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such filing.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">Number</P></TD>
    <TD STYLE="font-size: 11pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 11pt; width: 88%"><FONT STYLE="font-size: 11pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">99.1</FONT></TD>
    <TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">Phibro Animal Health Corporation press release, dated January 25, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">Date: January 25, 2016</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">PHIBRO ANIMAL HEALTH CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; width: 6%"><FONT STYLE="font-size: 11pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 11pt; width: 44%"><FONT STYLE="font-size: 11pt">/s/ Thomas G. Dagger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">Name:</FONT></TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">Thomas G. Dagger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">Title:</FONT></TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">Senior Vice President, General Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 11pt">and Corporate Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1600238_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><img src="logoex99-1.jpg"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>Phibro Animal Health Corporation Announces Closing of Acquisition
of Business of MVP Laboratories, Inc.</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>TEANECK, N.J., January 25, 2016 (GLOBE
NEWSWIRE)</B> &ndash; Phibro Animal Health Corporation (&ldquo;Phibro&rdquo;) (NASDAQ:PAHC) today announced it has completed its
purchase of the assets of MVP Laboratories, Inc. (&ldquo;MVP&rdquo;), a developer, manufacturer and marketer of livestock vaccines,
vaccine adjuvants and other products based in Omaha, Nebraska. Phibro previously announced an agreement to purchase the assets
of MVP Laboratories, Inc. on January 12, 2016.</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>About Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Phibro Animal Health Corporation is a diversified global developer,
manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry,
swine, cattle, dairy and aquaculture. The company reported net sales of&nbsp;$749 million for the fiscal year ended June 30, 2015.
For further information, please visit www.pahc.com.</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0.3pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>Contact</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Phibro Animal Health Corporation</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Richard Johnson</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">+1-201-329-7300</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="color: Blue"><U>investor.relations@pahc.com</U></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>This communication contains forward-looking
statements, which reflect Phibro&rsquo;s current views with respect to business plans or prospects, the transactions described
herein, and other future events. You can identify forward-looking statements by the fact that they do not relate strictly to historical
or current facts. These statements may include words such as &ldquo;aim,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;forecast,&rdquo; &ldquo;outlook,&rdquo; &ldquo;potential,&rdquo; &ldquo;project,&rdquo;
&ldquo;projection,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;believe,&rdquo; &ldquo;may,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;can,&rdquo; &ldquo;can have,&rdquo;
&ldquo;likely,&rdquo; the negatives thereof and other words and terms of similar meaning in connection with any discussion of
the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties
materialize, or if management&rsquo;s underlying assumptions prove to be incorrect, actual results may differ materially from
those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made.
Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual
Report on Form 10-K and our Quarterly Reports on Form 10-Q, including in the sections thereof captioned &ldquo;Forward-Looking
Statements&rdquo; and &ldquo;Risk Factors.&rdquo; These filings and subsequent filings are available online at <FONT STYLE="color: Blue"><U>www.sec.gov</U></FONT>,
<FONT STYLE="color: Blue"><U>www.pahc.com</U></FONT>, or on request from Phibro.</I>&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logoex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logoex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ / "[ P$1  (1 0,1 ?_$ -4   (" @,! 0
M       )!PH&" ,%"P0! 0 !! ,! 0              !08'" (#! $)$
M!@$!!@4 !@4&" \    ! @,$!08'"  1%187"2$2$Q08,4$B(]0*420EEE=A
M8D.D91DR,R8GETA8&H&AT5)RDF.3-$0UA=8H.!$  0($ P,&" L& P,-
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M2_9,+%NO+=P8=J VI#;6^9!GL).[F$*B2_-B855335+HTS$!5"%4*!LCT$#
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MJ/0.ZD)608Q<>U3 14<OY)TBR9-TP !$3KNER$#^4=I?6M#3:G7#)M*2HGF
M$R?(!"( 20!O,.*[@W9+U']O##%>SQD'(^*<B4>6MD'29=&F#9(VP5F?L3)\
M[B0=1T]'IM92,65CE4#KMG J)J^412\AA.6(M ]\^G>\"\.6.WT]53UJ&E.)
MS,!0M"" J129I.T&1$B)[9[(6[E8JFVL"H<4A394!LF""=V^$U;2_"'%GC2S
MJ:MM"_+=ZT(&8E7OMD\W2NGG%2JZZH^VBLQDQO(VFOQICFW$9,F]FGG8)DW
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MKM'CMY'NUD$$??(&.JH&X1W;APT35NV_55#=&J-ZX*I'TO9#8.)>6<0]5*R
M" 2<)V"/:] =HW&E.);"TE.([A/9RD?'%.\/R^&G0H 4.\!I@ "@   0]#\
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MO[NIYC/@;MV:O<D-W!6LFTPM::O!+>H":A+%D1%+'L =N.\#"X2EK0B<N[Q
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M^51] BO=I7Q,XSSJ;T\X5;IBJ.4<TXVI;H@!O (F9M<8C.K'_0DW@P<J'$?
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MV,$5I_S1&82TS0UC?$C9R=&1S;G:OD<H$.("YJ^-8B4N$J!R%\3I$L/!]_U
M)@_2&UC_ '9;1QFMJF[*$VZ*A5+P+>4EM/U,R&MJQ_+H$,\KC@^!(G\<HH1^
M8/Y?^J;_ )-KTQ'LXO2?E7</C6]*>H#-SIL!'66LV-JI&KG3W*JU[%%9:H)F
M3.8H&%N-CN,D0=P[A.D/UAM2/WH+OQ.J*"RI/1I*(N$?/?6?/@;1Y##_ -),
MX:1RH/RW)>1(]),6D-JQP[(-B"/*.[A&8BY\US:LLMH.3O(VV9VOR< N83*
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MA30J9N4[KS2GFTU('X<VD*49%6&1"I'9&HW>W)2M92K E)4#@V*"2$DIY]I
MY)\D;IZ>-26!LYS=VA\+-5=U/IF%;Q8YE&LM(*#<16<J.KD:A,F\@@<OOYAO
M4%D7;YN) ]B5ZB!C"*FX&9J+3M\L5.S47M0 =>J6TI*RI0-,YE.D@[DY@*4F
M?2PJYH[J:JIGRH,;DI2292$E#$/++:>:<:]N^ZQIA:.W;06&4UQ:.W+05VU1
MBSMEQ;+J("LW.:S$,=NJ*?F(82E$2B B ?1M59SWE.[QMQ367<CA41,,(D9&
M4Q]]N,ICP0Q5=Z.FDK*,-49$B8;3(R,ICI[N:/D4[KFEU9-1%:'RLJDJ0R:J
M2E,B#IJ)G*)3IJ$-:!*<ARB(" AN$-L1[S'=X#,-W0$?T$?[Z,?]4M-?L57L
MT_;C6^>U*=J*TR1YFRZ0*58)=545UI2:TP8>DY%=8PB)E5WKTRSE<XB(B(G,
M.\=G$Q[Y%II6\FFN&I&V0/52I8 \0%3(1RJ[Q=&K,U4[Q/A91]J)=I'<5T-8
MSCSQ.-\56/'T6H)1/&TC$E,JD><2>!1.S@9I@W,)?JWE\-DFM]ZG1MR<S;BN
M]5#O.X@+/PJ?)C<WWFZ5:&%IJI2/ TD?$N,T-W8M,!"F,,5EH0*43" 4Z*$=
MP!O'<'-/B/AMPGWF.[L"9:N<A_01_OHV'O3TT!/!5^S3]N-D\CZRM/\ A\S5
M/*5JF:.=?%"N:GAY2CW5['PF/&S^,AWDM.ST# 3%=C736=FV4>+0SL72CUX@
MBD10RR?FL_IO3E[U7;6+G9J?&S4.-MI2I;2',QQO,2@MJ6%8@@*4H@%*0E1*
MI))A\]8TJ6TN.%2 IH.;4G8DRWR! () (GOV1D/RIT^>_P"&=4('W77OXO\
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M6<;J?A.(;SL>3F)Q;O5Q"?FAQ?<#Z3=2<J]2NHW"?CUA7WW*G*'!N0^;-1/
MN&<9^\]QU[Y.XAZ_ZO[S@/\ Y?W6WW)[O.LNJ:/JCA9\=48,>9/,RZ.<\.R7
M"<1@EMPY_P K!%H[CD9BLS%@RD;I2PS7*7T\,_HPO'_Z4[O]:3R]2?[-]A[W
MS?\ ==<?4_\ ?^)?]IM(W_S2?_M<^&\,Y?\ #?[+!X(3O[#^MZWG^W]:<?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
